CorMedix posted preliminary third-quarter 2025 results showing more than $100 million in net revenue, at least $85 million from DefenCath, and a pro forma top line above $125 million when including Melinta for the whole period. The company raised 2025 pro forma revenue guidance to at least $375 million, expects at least $70 million in Q3 adjusted EBITDA, and forecasts at least $30 million of run-rate operating synergies from the Melinta acquisition by year-end, with additional savings in 2026. Enrollment has been completed in the phase III RESPECT study evaluating once-weekly rezafungin (Rezzayo) for prophylaxis in allogeneic transplant recipients, with data expected in the second quarter of 2026.
The numbers signal more than a one-quarter beat. CorMedix appears to be crystallizing a hybrid model that marries a high-need infection prevention asset in dialysis with a scaled hospital anti-infectives platform, using portfolio breadth and contracting leverage to convert formulary access into earnings. The company is testing whether consolidation plus disciplined medical evidence can finally make anti-infectives investable again for a field long starved of viable commercial archetypes.
Why it matters now comes down to utilization, reimbursement, and stewardship. DefenCath’s outperformance reflects adoption by a large dialysis organization and growing use across other customers, suggesting that infection prevention economics are resonating within a bundled payment environment. Suppose real-world data show reductions in catheter-related bloodstream infections and hospitalizations. In that case, dialysis providers can justify budget impact, payers can claim downstream savings, and patients may see fewer sepsis-related disruptions to care. The near-term test is operational: sustained supply, consistent clinical outcomes at scale, and expansion into adjacent catheter-dependent settings such as total parenteral nutrition and pediatrics, where CorMedix is already investing clinically.
On the hospital side, Melinta’s portfolio gives CorMedix immediate reach into infectious diseases, critical care, and transplant centers. Yet formulary wins in 2025 and 2026 will hinge on stewardship-aligned value stories and contracting strategies that bundle complementary agents without triggering restrictive use. Rezzayo prophylaxis is the potential step-change. If phase III reads out favorably, once-weekly echinocandin prophylaxis in allogeneic transplant patients could open a multibillion-dollar category. Still, adoption will require head-to-head credibility versus entrenched azole and echinocandin regimens, clear safety advantages, and RWE that convinces transplant pharmacists and committees to move protocols.
The bar for catheter lock solutions and anti-infective brands rose for competitors. Citrate-based locks, antimicrobial catheters, and hospital antibiotics with narrower labels will face a contracting environment increasingly shaped by portfolio economics and infection outcome metrics. For payers, the combination creates new opportunities for outcomes-based agreements linking infection reduction to reimbursement, particularly in ESRD and high-cost transplant episodes. For HCPs, the shift underscores a growing expectation that anti-infective innovation arrive with pragmatic dosing, stewardship compatibility, and robust post-market evidence rather than solely registration trial data.
CorMedix ends Q3 with approximately $56 million in cash and is guiding to about $100 million by year-end, a trajectory that, if maintained, reduces financing overhang and supports continued field investment and supply chain scaling. The strategic question is whether the company can translate near-term momentum into a durable advantage: expand DefenCath beyond hemodialysis without diluting outcomes, turn Melinta’s hospital footprint into a formulary flywheel, and convert a single high-profile readout in transplant prophylaxis into a new standard of care. If it executes on all three, CorMedix could become a template for how infection prevention and treatment can be commercialized sustainably; if not, 2026 may remind the industry how unforgiving stewardship-era markets can be.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
